Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. by Helsten, Teresa et al.
UC San Diego
UC San Diego Previously Published Works
Title


















eScholarship.org Powered by the California Digital Library
University of California
CLINICAL
Fibroblast growth factor receptor signaling in hereditary
and neoplastic disease: biologic and clinical implications
Teresa Helsten1 & Maria Schwaederle1 & Razelle Kurzrock1
Published online: 30 July 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Fibroblast growth factors (FGFs) and their recep-
tors (FGFRs) are transmembrane growth factor receptors with
wide tissue distribution. FGF/FGFR signaling is involved in
neoplastic behavior and also development, differentiation,
growth, and survival. FGFR germline mutations (activating)
can cause skeletal disorders, primarily dwarfism (generally
mutations in FGFR3), and craniofacial malformation syn-
dromes (usually mutations in FGFR1 and FGFR2); intrigu-
ingly, some of these activating FGFR mutations are also seen
in human cancers. FGF/FGFR aberrations reported in cancers
are mainly thought to be gain-of-function changes, and several
cancers have high frequencies of FGFR alterations, including
breast, bladder, or squamous cell carcinomas (lung and head
and neck). FGF ligand aberrations (predominantly gene am-
plifications) are also frequently seen in cancers, in contrast to
hereditary syndromes. There are several pharmacologic
agents that have been or are being developed for inhibition
of FGFR/FGF signaling. These include both highly selective
inhibitors as well as multi-kinase inhibitors. Of note, only four
agents (ponatinib, pazopanib, regorafenib, and recently
lenvatinib) are FDA-approved for use in cancer, although
the approval was not based on their activity against FGFR.
Perturbations in the FGFR/FGF signaling are present in both
inherited and malignant diseases. The development of potent
inhibitors targeting FGF/FGFRmay provide new tools against
disorders caused by FGF/FGFR alterations.
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1 Introduction
One of the most important advances in tumor biology is the
recognition that cancer is frequently driven by inherited or
acquired alterations in specific gene(s) or their products [1,
2]. Genomic alterations include changes in expression that
can result from mutation, deletion, gene amplification, and/
or translocation. Complicating matters, cancers often harbor
multiple genetic alterations, but one or a few of these are
thought to be primarily responsible for neoplastic behavior
in any given tumor. These are the so-called Bdriver muta-
tions,^ while Bpassenger mutations^ may have a more nu-
anced impact. A literature review suggests that over 1 % of
human genes can be implicated as cancer drivers when they
are mutated, with protein kinases comprising the largest sub-
group of genes altered [3].
Among human signaling pathways, fibroblast growth fac-
tor (FGF)/fibroblast growth factor receptor (FGFR) is one of
the pathways most enriched in non-synonymous mutations,
including several candidate driver mutations [3]. A computa-
tional method designed to identify driver mutations within
protein kinase datasets successfully identified multiple aberra-
tions in the FGF/FGFR machinery [4]. In keeping with other
genes implicated in neoplastic behavior, FGF/FGFR signaling
is also involved in development, differentiation, growth, and
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survival mechanisms. Indeed, FGFR aberrations have been
identified in both hereditary and neoplastic human diseases.
Most of the reported FGFR mutations that cause heritable
human diseases are activatingmutations which increase recep-
tor signaling. These abnormalities are seen in craniofacial and
skeletal syndromes such as the craniosynostoses [5–7]
(Pfeiffer, Crouzon, Apert, Jackson-Weiss, Muenke, and
Beare-Stevenson syndromes) and dwarfism syndromes [8, 9]
( achondrop la s i a , t hana topho r i c dysp l a s i a , and
hypochondroplasia). The only reported inherited condition
caused by loss of FGFR function is an autosomal dominant
form of hereditary hypogonatotrophic hypogonadism 2 with
or without anosmia [10, 11], which is caused by loss of func-
tion of FGFR1 [10, 12, 13] or a missense mutation in FGF8
[14]. Intriguingly, some of the same activating FGFR muta-
tions seen in inherited syndromes are also seen in human
cancers [14, 15]. Furthermore, FGF/FGFR aberrations report-
ed in cancers are overwhelmingly thought to be gain-of-
function changes, including gene amplifications and gene re-
arrangements [16].
The goal of identification and characterization of driver
mutations in cancer is, ultimately, to create successful anti-
cancer therapies with which to prosecute these tumors; several
such therapies already exist, demonstrating proof of principle
[17, 18]. Furthermore, for some gene targets, drugs may im-
pact the course of cancer as well as non-malignant conditions
that are driven by abnormalities in the cognate signal. JAK2
aberrations, for instance, are found in myelofibrosis, and
JAK2 inhibitors such as ruxolitinib provide significant benefit
in such patients [19]. At the same time, the JAK2 inhibitor
tofacitinib can benefit patients with rheumatoid arthritis and is
approved for that indication [20]. In the case of FGF/FGFR,
multiple drugs targeting this pathway have entered the clinic
[16]. Herein, we discuss the landscape of diseases that are
driven by aberrant FGF/FGFR machinery.
2 Molecular biology of FGF/FGFR signaling
Fibroblast growth factors (FGFs) and their receptors (FGFRs)
are evolutionarily conserved transmembrane growth factor re-
ceptors with wide tissue distribution in all vertebrates. FGFs
and FGFRs share homologies among their respective groups
and with other signaling molecules. FGFRs in particular are
similar to other signaling receptors, including vascular endo-
thelial growth factor receptor (VEGFR), platelet-derived
growth factor receptor (PDGFR), and other receptor tyrosine
kinases [21]. However, there are important differences be-
tween the individual signalingmolecules that allow for precise
control of a full range of processes, including development,
cell survival, differentiation, motility, angiogenesis, and
carcinogenesis.
2.1 Receptors
In humans, there are five known FGFRs, called FGFR1–
FGFR4 and FGFRL1 (also known as FGFR5). FGFR1–
FGFR4 are typical growth factor receptor tyrosine kinases,
with extracellular immunoglobulin (Ig)-like domains and in-
tracellular tyrosine kinase domains, while FGFRL1 lacks the
intracellular kinase domain and has less clear function(s)[22,
23]. Upon binding of their ligands, the typical receptors
homo- or hetero-dimerize, leading to sequential phosphoryla-
tion of specific intracellular tyrosine residues and activation of
an intracellular signaling cascade and gene transcription [24]
(Fig. 1). The FGFR signaling pathway interacts with several
other important intracellular pathways, including PI3K/Akt,
Wnt, hedgehog, and bone morphogenic protein (BMP) [24,
25]. FGFR1–4 have different ligand specificities based on
developmental aspects, tissue distribution, and RNA splicing
variation [26]. For example, the FGFR2b isoform is predom-
inantly expressed in epithelial cells, while the FGFR2c iso-
form is expressed predominantly in mesenchymal cells, and
switching from FGFR2b to FGFR2c occurs during progres-
sion and invasion of prostate and bladder cancers [27].
2.2 Ligands
There are 18 human ligands for FGFRs (Fig. 1). They are
FGF1 (acidic FGF), FGF2 (basic FGF), FGF3, FGF4,
FGF5, FGF6, FGF7 (KGF), FGF8, FGF9, FGF10, FGF16,
FGF17, FGF18, FGF19, FGF20, FGF21, FGF22, and
FGF23. FGF11–14 are not ligands for FGFRs and are known
as FGF homologous factors (FHF1–4) [28, 29]. There is no
human FGF15 (FGF15 is the mouse equivalent of human
FGF19) [30]. The FGFR ligands are secreted proteins that
bind to the extracellular matrix, thereby restricting their influ-
ence to the tissue where they are produced (autocrine or para-
crine function). However, three of the FGFs—FGF19,
FGF21, and FGF23—bind less tightly to extracellular matrix
heparin sulfates, so they are able to act systemically in an
endocrine fashion (hormone-like), allowing them to spread
from their production site into the circulation [30, 31]. Most
FGFs are secreted proteins with cleavable amino terminal por-
tions, but FGF9, FGF16, and FGF20 have non-cleavable se-
cretion sequences, and FGF1 and FGF2 have no secretion
sequences, although they are found in the extracellular com-
partment, suggesting an alternate process of release [29, 32].
Most FGFs are released from binding to the extracellular ma-
trix via action of heparin sulfate proteoglycans and/or fibro-
blast growth factor–binding protein (FGFBP1)[33].
2.3 FGF/FGFR interaction and function
In general, FGFs are promiscuous, andmost can bind to any of
the four main FGFRs, although some of the FGF/FGFR
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ligand/receptor pairs differ in their affinities (Fig. 1c). FGFs
interact with cell surface heparan sulfate proteoglycans
(HSPGs) and with the transmembrane protein Klotho (for
the hormone-like FGF19, 20, 23) to stabilize binding to
FGFRs. Ornitz et al. [34, 35] systemically investigated affin-
ities of FGFs for each FGFR isoform and showed, for exam-
ple, that FGFR2b is a high-affinity receptor for FGF1, FGF7,
FGF10, and FGF22, while FGFR2c has high affinity for
FGF1, FGF2, FGF4, FGF6, FGF8, FGF9, and FGF20. But,
differential expression of either FGFs or FGFRs in time or
tissue may also contribute to tissue-specific effects of FGF/
FGFR signaling. For example, FGF1 and FGF2 are expressed
in both embryonic and adult tissues, while FGF7–FGF9 are
predominantly expressed in developing or in restricted adult
tissues [36].
The differences in activity/function of the different FGF/
FGFR pairs are also highlighted by murine gene knockout
experiments. Mice heterozygous for FGFR knockout muta-
tions develop normally, so haplo-insufficiency is not likely
to be a factor [37]. However, mice homozygous for FGFR1
or FGFR2 null mutations die in utero, and FGFR3-null mice
develop normally other than overgrowth of cancellous bones
and deafness [37]. Most of the FGFs have also been knocked
out in mouse models, with varying phenotypic effects, includ-
ing lethality (FGF4, FGF8, FGF9, FGF10, FGF19, FGF18,
and FGF23), defects in neuromusculoskeletal development or
function (FGF2, FGF3, FGF6, FGF7, FGF12, FGF14,
FGF17, FGF18), cardiac defects (FGF2, FGF9, FGF16,
FGF19), and no identifiable abnormality (FGF1) [29].
2.4 Activation of signaling
To signal, FGFs have to be released from the extracellular
matrix by heparinases, proteases, or specific fibroblast growth
factor–binding protein (FGFBP1). FGFBP1 are secreted
Fig. 1 FGF/FGFR activation in cancer and inhibitors. a The activation of
FGF/FGFR signaling in cancer. The structure of FGF/FGFR comprises
two receptor molecules, two FGFs, and one heparan sulfate proteoglycan
chain. The FGFRs are formed by three immunoglobulin domains (IgI–
III), a transmembrane helix, and intracellular tyrosine kinase domains.
The mechanisms driving FGF signaling in cancer can be divided into
two categories: first, genomic alterations of FGFR that can lead to
ligand-independent receptor signaling and, second, alterations that
support a ligand-dependent signaling activation. Following FGF
binding to FGFR and heterodimerization, the tyrosine kinase domains
phosphorylate each other, leading to the activation of key downstream
pathways. b Examples of FGF/FGFR inhibitors; asterisk denotes FDA-
approved drugs in cancer; Ab=Antibody; FP-1039 (GSK3052230) is a
ligand trap, i.e., sequesters FGFs and inhibits their signaling [71]. c The
interactions between FGFs and FGFRs; references: Guillemot et al. [32],
Powers et al. [191], Ornitz et al. [192], Zhang et al. [34]. Interaction
between FGF ligands and receptors is an evolving field; variability may
be observed between studies and tissue types. 1FGF11-14 are not ligands
for FGFRs and are known as FGF homologous factors (FHF1–4)[28, 29].












C. Interactions between FGFs and FGFRs
FGF Ligands FGF Receptors
FGF1 FGFR1, FGFR2, FGFR3, FGFR4
FGF2 FGFR1, FGFR2, FGFR3, FGFR4
FGF3 FGFR1, FGFR2
FGF4 FGFR1, FGFR2, FGFR3, FGFR4
FGF5 FGFR1, FGFR2
FGF6 FGFR1, FGFR2, FGFR4
FGF7 FGFR2, FGFR4
FGF8 FGFR1, FGFR2, FGFR3, FGFR4
FGF9 FGFR2, FGFR3, FGFR4
FGF10 FGFR1, FGFR2
FGF11-14 Not FGFRs ligands1
FGF16 FGFR2, FGFR3, FGFR4
FGF17 FGFR1, FGFR2, FGFR3, FGFR4
FGF18 FGFR2, FGFR3, FGFR4
FGF19 FGFR1, FGFR2, FGFR3, FGFR4
FGF20 FGFR1, FGFR2, FGFR3, FGFR4
FGF21 FGFR1, FGFR2, FGFR3, FGFR4
FGF22 FGFR1, FGFR2
FGF23 FGFR1, FGFR2, FGFR3, FGFR4
FGFR FGF Ligands
FGFR1 FGF1-6, FGF8, FGF10, FGF17, FGF19-23
FGFR2 FGF1-10, FGF16-23
FGFR3 FGF1-2, FGF4, FGF8-9, FGF16-21, FGF23
FGFR4 FGF1-2, FGF4, FGF6-9, FGF16-21, FGF23
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heparin proteins that reversibly bind FGF1 and FGF2, releas-
ing them from the extracellular matrix and increasing the local
levels of free ligand available for receptor binding [38].
FGFBP1 is secreted by keratinocytes and human epidermal
carcinomas, particularly squamous cell carcinomas [33, 38].
Its expression is seen in development, wound healing, cancer,
and angiogenesis, and it is downregulated by pharmacologic
agents in vitro [33]. The fibronectin-leucine-rich transmem-
brane protein 3 (FLRT3) is co-expressed with FGF8 during
development, co-immunoprecipitates with FGF8/FGFRs,
physically interacts with FGFRs via its fibronectin type III
domain, and increases activity through the MAPK pathway,
facilitating FGFR signaling [39, 40].
2.5 Inhibition of signaling
FGF/FGFR signaling is negatively regulated by several mech-
anisms. FGFR stimulation activates sprouty proteins
(SPRY1–4), which in turn negatively feedbacks on FGF/
FGFR/MAPK signaling by interacting with growth factor re-
ceptor bound protein 2 (GRB2), son of sevenless homolog 1
(SoS1), and/or RAF proto-oncogene serine/threonine-protein
kinase (RAF1) [41, 42]. Intriguingly, sprouty proteins are
thought to be general inhibitors of receptor tyrosine kinase
growth factor signaling via inhibition of Ras-MAPK signal-
ing, but their behavior differs among specific growth factor
receptors. For example, sprouty protein inhibits FGFR signal-
ing but potentiates epidermal growth factor receptor (EGFR)
signaling [43]. The cytoplasmic domain of similar expression
to FGF (SEF, also known as IL-17 receptor D) interacts with
the cytoplasmic domain of FGFR and inhibits downstream
signaling of the pathway [43]. Finally, MAP kinase phospha-
tases (MKPs) dephosphorylate ERKs and thereby downregu-
late the signaling pathway. MKP3 functions within the cyto-
plasm, whereas MKP1 is localized in the nucleus [43].
FGFRL1 is the atypical receptor that lacks an intracellular
kinase domain. Like the other FGFRs, it is found in all verte-
brates, is expressed in a wide variety of tissues, and binds to
some FGF ligands. In vitro experiments show that FGFRL1
binds FGF3, FGF4, FGF8, FGF10, and FGF22, but not the
other FGFs tested [44]. Unlike FGFR1–4, it is shed from cell
membranes [44], suggesting that it may serve as a ligand trap
to negatively regulate signaling [45]. Other regulatory mech-
anisms might include heterodimerization with other FGFRs to
prevent trans-autophophorylation and thereby negatively reg-
ulating intracellular signaling or by increasing membrane
turnover rates of the other FGFRs, but there is currently no
evidence that these mechanisms exist [45]. The exact func-
tions of FGFRL1 are not known. FGFRL1-null mice die in
infancy with diaphragmatic defects and renal agenesis [45],
and there are case reports of FGFRL1 mutations in human
disease: craniosynostosis [46] and ovarian cancer [47].
3 FGF/FGFR aberrant signaling in human disease
3.1 Inherited syndromes
Several types of inherited syndromes are due to germline aber-
rations in FGFR. These include craniosynostosis syndromes and
achondroplasia [48], mainly due to gain-of-function mutations,
as well as loss-of-function anomalies associated with congenital
hypogonadotropic hypogonadism (Table 1). Interestingly, al-
though some of these aberrations are identical to those that, in
somatic form, are associated with cancer, for the most part, the
individuals with these hereditary syndromes have not been re-
ported to have an increased incidence of cancer. Apart from case
reports [49–53], there is no epidemiologic evidence that people
wi th cran iosynostos i s , dwarf i sm, or congeni ta l
hypogonadotropic hypogonadism are at increased risk for ma-
lignancy. This is possibly related to differential effects of activat-
ing FGFR mutations in cell or tissue type in the context of stage
of development. It is possible, for instance, that there are as yet
unknown anti-neoplastic compensatory effects in individuals
with these disorders, perhaps stemming from the presence of
germline FGFR aberrations during development as opposed to
the appearance of somatic FGFR mutations in human cancers.
3.2 Somatic aberrations in benign conditions
Somatic or acquired mutations in FGFR3 have been observed
in benign skin conditions like seborrheic keratosis and epider-
mal nevi [54, 55]. These aberrations are activating and, when
evaluated, are not seen in adjacent normal skin [55]. Many of
these are identical to mutations that are also seen in bladder
and/or cervical cancers.
3.3 Somatic aberrations in malignancies
Aberrations in FGFR and its ligands are common in malig-
nancy (Tables 2, 3, and 4 and Figs. 2 and 3). Across malig-
nancies, FGF anomalies are found in ≈14 % and FGFR in
≈7 % of malignancies [56] (FGF/FGFR in about 20 %).
3.3.1 FGFR alterations
While almost any FGFR genes can be altered in many cancer
types, some acquired genetic aberrations are more striking in
prevalence or in cancer type(s) than others. The most common
abnormalities reported to date are gene amplifications of
FGFR1–3 (Table 2). These are generally assumed to represent
activation or gain-of-function amplifications, but full molecu-
lar characterization of the effects of gene amplification within
specific cellular or cancer microenvironment contexts is not
fully available. The cancers in which FGFR gene amplifica-
tions are most frequent include bladder urothelial carcinomas
(FGFR1), squamous cell lung cancer (FGFR1), head and neck
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squamous cell cancer (FGFR1), uterine carcinosarcoma
(FGFR3), breast adenocarcinoma (FGFR1), and gastric ade-
nocarcinoma (FGFR2) (Tables 2 and 3, and Fig. 2). In fact,
FGFR2was first identified in a gastric cancer cell line, and it is
preferentially amplified/overexpressed in the diffuse type of
gastric cancer, which correlates with poor prognosis, at least in
a Japanese population [57]. More commonly, however, muta-
tions in FGFR3 characterize bladder carcinoma. Indeed, acti-
vating mutations of fibroblast growth factor receptor-3
(FGFR3) have been described in approximately 75 % of
low-grade papillary bladder tumors. In muscle-invasive dis-
ease, FGFR3 mutations are found in 20 % of tumors, but
overexpression of FGFR3 is observed in about half of cases
[58].
Loss-of-function alterations are relatively uncommon in
cancer (a pattern that is also seen in hereditary disorders).
However, there is at least one report indicating that some
melanoma cell lines demonstrate FGFR2 loss of function [59].
FGFR1 amplification is prevalent in both squamous cell
carcinoma of the lung and of the head and neck, suggest-
ing a possible common underlying mechanism of carcino-
genesis in these smoking-related carcinomas. Perhaps more
importantly, development of FGFR1 inhibitors represents a
viable targeted therapy for use in squamous cell lung can-
cers [60, 61].
3.3.2 FGF alterations
FGF abnormalities are for the most part amplifications (Fig. 3
and Table 4). There are few reported data regarding the mech-
anism(s) of action of these amplifications. Nevertheless, it
seems reasonable to hypothesize that abundance of ligand
could lead to increased receptor signaling, but the reality
may be more complex, perhaps relating to the stoichiometric
proportions of the different ligands present. Of note, three of
the ligands, FGF3, FGF4, and FGF19, are frequently co-
amplified on 11q13 [62]. This amplicon is present in several
cancers, including breast, bladder, and squamous cell carcino-
ma of the lung and head and neck (Fig. 3 and Table 4).
3.3.3 FGFR rearrangements
Chromosomal translocation gives rise to chimeric gene prod-
ucts with aberrant function (Table 2). In general, fusion gene
proteins result from the fusion of a Bpartner gene^ with a tyro-
sine kinase domain derived from the FGFR family member
gene. As a result of their constant dimerization state, they are
constitutively active in the absence of ligand. The FGFR1 gene
can be fused to other genes including BCR, ZNF198, CEP110,
FGFR1OP1, FGFR1OP2, HERVK, TRIM24, LRRFIP1, and
MYO18A, in the 8p11 myeloproliferative syndrome manifested
Table 2 Specific examples of FGFR alterations in cancer
Activating
aberrations
Examples of disease(s) (most common) Reference(s)
Amplifications
FGFR1 Squamous cell carcinoma of lung, breast adenocarcinoma, bladder urothelial
carcinoma, head and neck squamous cell carcinoma
[78, 120–123] [124]
[125, 126]
FGFR2 Gastric adenocarcinoma [127–129]
FGFR3 Uterine carcinosarcoma, ovarian cystadenocarcinoma, sarcoma [56] [130] [56, 131]
FGFR4 Kidney, renal clear cell carcinoma [56]
Mutations
FGFR1 Stomach adenocarcinoma, melanoma [127] [56, 132]
FGFR2 Uterine (endometrial carcinoma), melanomaa [133] [56, 59, 132]
FGFR3 High-grade bladder cancer, cervical cancer [124, 134, 135] [136]
FGFR4 Rhabdomyosarcoma, melanoma [137, 138] [132]
Rearrangements
FGFR1 8p11 myeloproliferative syndrome/fusions partners: BCR, ZNF198, CEP110,
FGFR1OP1, FGFR1OP2, HERVK, TRIM24, LRRFIP1, MYO18A, CPSF6
[63]
Rhabdomyosarcoma/fusions partner: FOXO1 [64]
Glioblastoma/fusions partner: TACC1 [68]
Salivary gland/fusions partner: PLAG1 [139]
FGFR2 Cholangiocarcinoma/fusions partners: AHCYL1,BICC1 [140, 141]
Breast/fusions partners: AFF3, CCDC6, CASP7 [141]
FGFR3 Multiple myeloma/fusions partner: MMSET [65]
Glioblastoma, bladder carcinoma, head and neck squamous cell
carcinoma/fusions partner: TACC3
[68, 135, 141]
a FGFR2 mutations may be loss of function
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by myeloproliferative neoplasms and peripheral blood eosino-
philia without basophilia [63]; it is fused to the FOXO1 gene in
alveolar rhabdomyosarcoma, and the FOXO1-FGFR1 fusion
gene is amplified [64]. TheFGFR3 gene is fused to theMMSET
gene as a result of a t(4;14)(p16.3;q32) chromosomal translo-
cation in 10–20 % of multiple myeloma [65]; it is fused to the
ETV6 gene in peripheral T cell lymphoma with a
t(4;12)(p16;p13) chromosomal translocation [66]. In glioblas-
tomamultiforme,FGFR1 andFGFR3 genes are fused to neigh-
boring TACC1 and TACC3 genes due to interstitial deletions,
respectively [67, 68].
4 FGF/FGFR signaling inhibitors and cancer
therapy
4.1 FDA approved drugs that target FGFR
Only four drugs (ponatinib, regorafenib, pazopanib, and more
recently lenvatinib) are FDA-approved for use in human can-
cers (Table 5). Ponatinib is a multi-tyrosine kinase inhibitor
that was approved for imatinib-resistant chronic myelogenous
leukemia (CML) and Philadelphia chromosome-positive (CP)
acute lymphoblastic leukemia (ALL). The efficacy results
Table 3 Examples of FGFR mutations and copy number alterations in cancer





Bladder urothelial carcinoma 35 % FGFR1 14 % FGFR3 19 %
FGFR2 3 % FGFR4 6 %
FGFR1 almost all amplifications




27 % FGFR1 18 % FGFR3 4 %
FGFR2 4 % FGFR4 2 %
FGFR1: Almost all are gene amplifications [56, 142]
Uterine corpus endometrioid
carcinoma
24 % FGFR1 7 % FGFR3 5 %
FGFR2 14 % FGFR4 4 %
FGFR1 approximately 50 % amplification
and 50 % mutations
FGFR2 almost all mutations
[56, 133]
Gastric adenocarcinoma 23 % FGFR1 6 % FGFR3 4 %
FGFR2 10 % FGFR4 5 %
Approximately 50 % amplifications/deletions
and 50 % mutations
[56, 127]
Breast adenocarcinoma 20 % FGFR1 14 % FGFR3 2 %
FGFR2 3 % FGFR4 2 %
Almost all are amplifications [56, 120, 143–145]
Melanoma 20 % FGFR1 5 % FGFR3 5 %
FGFR2 11 % FGFR4 5 %
FGFR2 mostly mutations [56]
Ovarian serous
cystadenocarcinoma
20 % FGFR1 5 % FGFR3 8 %
FGFR2 4 % FGFR4 4 %
Almost all amplifications, rare mutations [56, 130]
Head and neck squamous
cell carcinoma
17 % FGFR1 10 % FGFR3 4 %
FGFR2 1 % FGFR4 1 %
Majority of amplification with about 20 %
deletion and mutations (each), and few fusions
[56, 146, 147]
Lung, adenocarcinoma 14 % FGFR1 6 % FGFR3 2 %
FGFR2 4 % FGFR4 4 %
Approximately 50 % amplifications and 50 %
mutations, with predominance of FGFR1
amplification
[56, 148–150]
Prostate adenocarcinoma 11 % FGFR1 6 % FGFR3 1 %
FGFR2 3 % FGFR4 1 %





11 % FGFR1 2 % FGFR3 1 %
FGFR2<1 % FGFR4 7 %
Majority amplifications [56, 152]
Sarcoma 10 % FGFR1 4 % FGFR3 4 %
FGFR2 1 % FGFR4 2 %
Majority amplifications (n=2 deletions) [56, 131]
Renal papillary cell 9 % FGFR1 4 % FGFR3 2 %
FGFR2 1 % FGFR4 3 %
All mutations, only 2 cases had amplification [56]
Colorectal adenocarcinoma 8 % FGFR1 5 % FGFR3 1 %
FGFR2 1 % FGFR4 1 %
FGFR1 about 60 % amplification, rest
mutations/deletion
[56, 153]
Glioblastoma 6 % FGFR1 0 % FGFR3 2 %
FGFR2 3 % FGFR4 1 %
FGFR2 mostly deletions [56, 154]
Adenoid cystic carcinoma 5 % FGFR1 3 % FGFR3 0 %
FGFR2 0 % FGFR4 2 %
FGFR1 amplification and deletion (1 each)
FGFR4 mutation (n=1)
[56, 155]
Brain, lower grade gliomas 5 % FGFR1 0 % FGFR3 1 %
FGFR2 3 % FGFR4 1 %
Most are deletions, with few amplifications
and mutations
[56, 156]
Acute myeloid leukemia 1 % FGFR1<1 % FGFR3 0 %
FGFR2 0 % FGFR4<1 %
1 amplification, 1 deletion, no mutations [56, 157]
Thyroid carcinoma <1 % FGFR1 0 % FGFR3<1 %
FGFR2<1 % FGFR4<1 %
Two amplifications, one mutation [56]
See also Fig. 2 for illustration (bar graph)
FGF fibroblast growth factor, FGFR fibroblast growth factor receptor
a Data extracted/analyzed based on cbioportal at http://www.cbioportal.org/public-portal (accessed November 2014). Most of the studies included >200
patients
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demonstrated a 54%major cytogenetic response (MCyR) rate
in patients with CP-CML, and seventy percent of patients with
CP-CML with the T315I mutation in BCR-ABL achieved
MCyR. In addition of targeting BCR-ABL, ponatinib can
also inhibit members of the VEGFR, PDGFR, FGFR
(IC50=2 nM for FGFR1), and SRC families of kinases,
KIT, or RET, with IC50 between 0.1 and 20 nM. Of note,
ponatinib was briefly taken off the market by the FDA
because of concerns about cardiovascular side effects
(clotting), but soon after, it was returned to the market
with updated safety monitoring recommendations. Regoraf-
enib was approved for imatinib-resistant gastrointestinal
stromal tumor (GIST) and metastatic colorectal cancer,
based on a statistically significant survival prolongation
observed in patients randomized to receive regorafenib
(6.4 vs 5.0 months in the placebo arm, P=0.01).
Regorafenib, and its active metabolites inhibit multiple
membrane-bound and intracellular kinases including those
in the RET, VEGFR1, VEGFR2, VEGFR3, KIT,
PDGFR-α and -β, FGFR1-2, and Abl pathways.
Pazopanib was approved for advanced renal cell carcino-
ma (based on a progression-free survival of 9.2 months
compared to 4.2 months in the placebo arm), as well as
soft tissue sarcomas (improved progression-free survival:
4.6 months versus 1.6 for patients who received placebo).
Pazopanib is a multi-tyrosine kinase inhibitor whose tar-
gets include VEGFR1-3, PDGFR-α and -β, FGFR-1 and -
3, and KIT. Lastly, lenvatinib is a multi-kinase inhibitor
(targets including VEGFR1–3, FGFR1–4, PDGFR-α, KIT,
and RET) indicated for the treatment of patients with lo-
cally recurrent or metastatic, progressive, radioactive
iodine-refractory differentiated thyroid cancer. The recent
Table 4 Examples of FGF ligand mutations and copy number aberrations in cancer





Head and neck squamous
cell carcinoma
54 % FGF3 28 % FGF12 19 %
FGF4 28 % FGF10 6 %
FGF19 28 % FGF23 5 %
Virtually all amplifications [56]
Bladder urothelial carcinoma 47 % FGF3 13 % FGF1711%
FGF4 12 % FGF10 9 %
FGF19 13 % FGF20 9 %
FGF3, FGF4, and FGF19 co-amplified
in approximately 12 % of cases
FGF17 and 20 mostly deletions
[56, 124]
Stomach cancer 47 % FGF3 7 % FGF12 8 %
FGF4 7 % FGF13 6 %
FGF19 7 % FGF14 5 %
FGF10 9 % FGF17 5 %
FGF3/4/19 co-amplified in 7 % of cases
FGF17 and FGF20 both deleted in 2 % of cases
[56, 127]
Lung, squamous cell carcinoma 46 % FGF3 12 % FGF12 26 %
FGF4 12 % FGF10 7 %
FGF19 13 %
Virtually all are gene amplifications [56, 142]
Cervical cancerb 42 % FGF12 25 % All are amplifications [56]




FGF17 and FGF20 mostly deletions
FGF3/4/19 co-amplified in 4 % of cases
[56, 148–150]
Melanoma 38 % FGF3 8 %
FGF4 6 %
FGF19 6 %
FGF3/4/19 co-amplified in about 7 % of cases [56]
Ovarian cystadenocarcinoma 38 % FGF3 5 % FGF6 5 %
FGF4 4 % FGF23 6 %
FGF19 4 % FGF12 13 %
Virtually all amplifications [56, 130]
Breast adenocarcinoma 35 % FGF3 15 % FGF17 6 %
FGF4 15 % FGF20 5 %
FGF19 15 %
High frequency of co-amplification of
FGF3/4/19. Similar results with TCGA,
Nature 2012 study (n=482)
[56, 120, 143, 145]
Adenoid cystic carcinoma 27 % FGF22 10 %
All others 5 %or less
Approximately 50 % deletions and 50 %
amplifications, rare mutations
[56, 155]
Prostate adenocarcinoma 22 % FGF17 8 %
FGF20 5 %
Majority are deletions, about 5 % cases
are co-deleted FGF17/20
[56, 151]
Colorectal adenocarcinoma 17 % All 5 % or less Majority of mutations, less amplifications
and rare deletion
[56, 153, 158]
See also Fig. 3 for illustration (bar graph)
FGF fibroblast growth factor
a Included FGFs with alteration frequency ≥5 % and at least 5 cases with the alteration. Extracted/analyzed in part based on cbioportal at http://www.
cbioportal.org/public-portal (accessed November 2014)
b Squamous cell carcinoma and endocervical adenocarcinoma. Abbreviations: FGF=fibroblast growth factor. See also Fig. 3 for illustration (bar graph)
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approval in February 2015 was based on an improved
progression-free survival (18.3 vs 3.6 months in the pla-
cebo group, P<0.001). The approvals of these four agents
(ponatinib, regorafenib, pazopanib, and lenvatinib), all
three of which are multi-kinase inhibitors, were not based
on activity against FGFR. Of interest, nintedanib is an
FGFR inhibitor that is FDA-approved for a non-cancer
indication—idiopathic pulmonary fibrosis (Table 5).
4.2 Experimental agents that target FGF/FGFR
There are several pharmacologic agents that have been or are
being developed for inhibition of FGFR via targeting of the
ATP binding site of the intracellular tyrosine kinase domain(s)
(Table 5). The inhibition varies by their affinities for FGFR
signaling, as most of these molecules are promiscuous kinase
inhibitors (inhibiting VEGF, PDGF, and many other TKIs in
addition to FGFR). Figure 1b gives examples of selective
versus non-selective FGFR inhibitors. Of note, the dual kinase
inhibitor (VEGFR/FGFR) lucitanib has shown activity in
FGFR1-amplified breast cancer, with an overall response rate
of 50 % [69]. There are also selective tyrosine kinase inhibi-
tors (TKIs) available (Table 5 and Fig. 1b). While several of
these agents are currently in clinical trials, none of the more
highly selective FGFR inhibitors (e.g., BGJ398 or AZD4547)
are currently FDA-approved. A recent study demonstrated
that Debio 1347 (a selective orally available FGFR1–3 inhib-
itor) displayed preferential anti-tumor activity against cells
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Uterine corpus endometrioid carcinoma
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Approximate frequency (%)
Fig. 2 Approximate frequencies
of FGFR alterations in diverse
cancers. Data was extracted/
analyzed based on cbioportal at
http://www.cbioportal.org/public-
portal (accessed November
2014). Most of the studies
included >200 patients.
Alterations in FGFR1, FGFR2,
FGFR3, and FGFR4 were
included. Please refer to Table 3













Lung, squamous cell carcinoma
Bladder urothelial carcinoma
Stomach cancer
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Approximate frequency (%)
Fig. 3 Approximate frequencies
of FGF ligand alterations in
diverse cancers. Data was
extracted/analyzed based on data




squamous cell carcinoma and
endocervical adenocarcinoma.
Please refer to Table 4 for more
details and additional references.
Abbreviations: FGF=fibroblast
growth factor
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with FGFR genetic alterations in a panel of 327 cancer cell
lines and xenograft models [70]. Debio 1347 is currently un-
der investigation for the treatment of patients harboring FGFR
genetic alterations.
Of interest, other types of agents have been developed. As
an example, FP-1039 is a soluble fusion protein, consisting of
the extracellular domains of human FGFR1 linked to the Fc
region of the human immunoglobulin G1; it is designed to
bind multiple FGF ligands [71] (TRAP molecule).
A large number of other drugs and indications are being
pursued. Some FGFR inhibitors have failed to meet their
phase III endpoints (Table 5). The majority of the failed trials,
however, have been performed in patient populations that
were not biomarker-selected.
4.3 Resistance mechanisms
In a recent phase 1 study reporting on patients with FGFR1-
amplified (identified by fluorescent/chromogenic in situ hy-
bridization) advanced or metastatic lung squamous cell carci-
noma (SCC) treated with the selective pan-FGFR inhibitor
BGJ398, only a limited number of patients achieved relatively
short-lived partial responses (2 of 17 patients, 11.7 %); re-
sponses lasted 3 and 8 months. These observations suggest
the existence of resistance mechanisms. Sohl et al. [72] report-
ed that resistance mutations at the Bgatekeeper^ residue may
arise (FGFR1 V561M mutation confers a 38-fold increase in
autophosphorylation and significant resistance to lucitanib),
leading to tumor progression and explaining the non-durable
responses. For instance, it has also been shown that the het-
erozygous gatekeeper mutation FGFR3 V555M appeared as a
mechanism of acquired resistance to selective FGFR inhibi-
tors [73]. Several other activating mutations were identified in
FGFR2-expressing cells treated with high concentrations of
dovitinib, and the multi-kinase inhibitor ponatinib inhibitory
activity was affected by the V565I gatekeeper mutation [74].
In addition, a previously undescribed FGFR3 variant was
identified as a key contributor to resistance in the MGH156-
1A cell line derived from a patient with acquired resistance to
EGFR TKIs [75], and follow-up studies clearly indicated that
FGFR inhibitors re-sensitized these cells to EGFR inhibitors.
Besides secondary mutations in the kinase domain, resis-
tance to FGFR kinase inhibitors may also occur through acti-
vation of alternative signaling pathways, as demonstrated by
Harbinski et al. [76] who showed a broad and versatile poten-
tial for tyrosine kinase receptor from the FGFR, HER, and
MET family to compensate for each other. Javidi-Sharifi
et al. [77] suggest that some patients with gastrointestinal stro-
mal tumor (GIST) treated with imatinib can develop a func-
tional dependence on FGFR3, illustrated by the fact that the
addition of the FGFR3 ligand FGF2 to GIST cells restored
KIT phosphorylation during imatinib treatment. Furthermore,
signaling crosstalk between KIT and FGFR3 activated the
MAPK pathway to promote resistance to imatinib. FGFR am-
plification and overexpression have also been related to poor
prognosis and endocrine resistance in breast cancer [78]. Of
note, relationships between cyclins and FGF/FGFRs have also
been reported at the protein level. For instance, a study
showed that FGFR4 contributed to the maintenance of
CCND1 via the mTOR translation pathway, and several other
studies demonstrated cooperation between FGFR and
CCND1 [79]. Finally, most patients with advanced cancer
have complex molecular portfolios, and hence there may be
multiple genomic drivers that are active and supplant the role
of FGFR [80–82]. In that context, it appears evident that iden-
tification of resistance mechanisms is crucial to crafting effec-
tive drug combinations.
5 Conclusion
The FGF/FGFR pathway is crucial to a variety of human
diseases. There are five known FGFRs, FGFR1–FGFR4 and
FGFRL1, and 18 human ligands for FGFRs. FGFR germline
mutations (activating) can cause skeletal disorders, primarily
dwarfism (generally mutations in FGFR3) and craniofacial
malformation syndromes (usually mutations in FGFR1 and
FGFR2). Loss-of-function mutations in FGF signaling are
seen in congenital hypogonadotropic hypogonadism (includ-
ing the Kallman syndrome variant with anosmia). Interesting-
ly, many of the aberrations that cause the inherited skeletal
disorders are also seen in human cancers.
The most common abnormalities in malignancies are gene
amplifications of FGFR1–3 or of the FGF ligands. The can-
cers in which FGFR gene amplifications are most frequent
include squamous cell lung cancer (FGFR1), head and neck
squamous cell cancer (FGFR1), bladder (transitional cell) can-
cer (FGFR1), endometrial cancer (FGFR1), gastric adenocar-
cinoma (FGFR2), breast adenocarcinoma (FGFR1), and pros-
tate adenocarcinoma (FGFR1). Point mutations are seen in all
FGFRs but are less frequent in FGFs. For instance, mutations
in FGFR3 are frequent in bladder carcinoma, and FGFR2
mutations in endometrial cancer, melanoma, and gastric tu-
mors (Tables 2 and 3).
Interestingly, somatic mutations in FGFR3 have been ob-
served in benign skin conditions such as seborrheic keratosis
and epidermal nevi (but not in adjacent normal skin) [54].
FGFR rearrangements are also observed in certain cancers
and characterize certain myeloproliferative disorders
(Table 2).
Importantly, there are several pharmacologic agents
that have been or are being developed for inhibition of
FGFR kinases. These include both highly selective inhib-
itors as well as multi-kinase inhibitors. Ponatinib, regoraf-
enib, pazopanib, and lenvatinib are already FDA-
approved for cancer, albeit not on the basis of their FGFR
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activity. Very few studies in cancer have been aimed at an
FGFR biomarker-selected population, and several of the
FGFR inhibitors have failed phase III studies in unselect-
ed patients. A multi-kinase inhibitor (nintedanib), which
suppresses FGFR1–3, was also recently FDA-approved
for idiopathic pulmonary fibrosis.
Whether or not FGFR inhibitors could also be used to
moderate the phenotype of inherited disorders due to
FGFR activation is an intriguing question. Of interest,
Garcia et al. [48] injected ia mouse model of achondro-
plasia with a soluble form of human FGFR3 (acting as a
decoy receptor and preventing FGF from binding to mu-
tant FGFR3), and effective maturation of growth plate
chondrocytes was restored in the bones of treated mice.
Of interest in this regard, individuals afflicted with the
inherited disorders associated with FGFR aberrations,
such as dwarfism, do not have an increased incidence of
cancer, despite having mutations that are often identical to
those somatic FGFR aberrations that characterize certain
tumors. The secondary modulatory influences that miti-
gate the risk of cancer in these individuals are of interest.
Whether or not treating them at an early age with FGFR
inhibitors would increase the later risk of cancer if the
inhibitors were withdrawn would need to be considered.
In summary, perturbations in the FGF/FGFR machinery
appear to underlie a variety of inherited syndromes, as well
as benign and malignant disorders. The advent of potent
FGFR inhibitors provides important new agents in the arma-
mentarium against diseases caused by FGF/FGFR
abnormalities.
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